Neurothera Labs (TSXV:NTLX) ROCE %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:NTLX Neurothera Labs Inc TSXV:NTLX
31 GF Score
Price C$0.33
! 2 Warning Signs
View Full Analysis

What is Neurothera Labs ROCE %?

Neurothera Labs TSXV:NTLX +12.07% 31 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates TSXV:NTLX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Neurothera Labs's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

Neurothera Labs  (TSXV:NTLX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Neurothera Labs ROCE % Related Terms

Neurothera Labs ROCE % Historical Data

* Premium members only.

The historical data trend for Neurothera Labs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurothera Labs ROCE % Chart

Neurothera Labs Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
ROCE %
-3.47 -19.96 -6.19 -8.54 -24.11

Neurothera Labs Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.37 -67.10 -6.54 -8.00 0.00
TSXV:NTLX
31GF Score
Neurothera Labs Inc TSXV:NTLX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurothera Labs ROCE % Calculation

Neurothera Labs's annualized ROCE % for the fiscal year that ended in Jan. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jan. 2025 )  (A: Jan. 2024 )(A: Jan. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jan. 2025 )  (A: Jan. 2024 )(A: Jan. 2025 )
=-0.253/( ( (1.223 - 0.042) + (1.073 - 0.155) )/ 2 )
=-0.253/( (1.181+0.918)/ 2 )
=-0.253/1.0495
=-24.11 %

Neurothera Labs's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jul. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jul. 2025 )(Q: Dec. 2025 )
=0/( ( (1.038 - 0.155) + (4.184 - 1.901) )/ 2 )
=0/( ( 0.883 + 2.283 )/ 2 )
=0/1.583
=0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Neurothera Labs (TSXV:NTLX) has a ROCE % of 0.00% as of Dec. 2025.
Is Neurothera Labs' ROCE % too high?
Neurothera Labs' current ROCE % is 0.00%. Overall, Neurothera Labs has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' ROCE % compare to LLY and JNJ?
Neurothera Labs' ROCE % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 6.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 6.94, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 6.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurothera Labs's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (TSXV:NTLX) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Neurothera Labs' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Neurothera Labs (TSXV:NTLX), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurothera Labs Business Description

Address 325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
31GF Score

Get the complete analysis for TSXV:NTLX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.33
Price